SARS-CoV-2-IN-1 manufacturers
- SARS-CoV-2-IN-1
-
- $1050.00
-
2025-08-22
- CAS:2412965-59-2
- Purity:
- Supply Ability: 10g
|
| | SARS-CoV-2-IN-1 Basic information |
| Product Name: | SARS-CoV-2-IN-1 | | Synonyms: | SARS-CoV-2-IN-1;Mpro inhibitor 13b;MPro 13b;SARS CoV 2 IN 1,SARSCoV2IN1;Carbamic acid, N-[1-[(1S)-1-(cyclopropylmethyl)-2-[[(1S)-2,3-dioxo-1-[[(3S)-2-oxo-3-pyrrolidinyl]methyl]-3-[(phenylmethyl)amino]propyl]amino]-2-oxoethyl]-1,2-dihydro-2-oxo-3-pyridinyl]-, 1,1-dimethylethyl ester;Mpro 13b-K | | CAS: | 2412965-59-2 | | MF: | C31H39N5O7 | | MW: | 593.67 | | EINECS: | | | Product Categories: | | | Mol File: | 2412965-59-2.mol |  |
| | SARS-CoV-2-IN-1 Chemical Properties |
| density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO|59.37|100| | | pka | 8.67±0.20(Predicted) |
| | SARS-CoV-2-IN-1 Usage And Synthesis |
| Description | MPro 13b is a coronavirus Mpro inhibitor. It inhibits SARS-CoV-2 infection of human Calu3 cells. | | Uses | SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively[1]. | | in vivo | SARS-CoV-2-IN-1 (3 mg/kg; subcutaneous) shows the Cmax is 126.2 ng/mL. The mean residence time for SARS-CoV-2-IN-1 is extended to 2.7 hours and the plasma half-life in CD-1 mice is 1.8 hour[1]. | | storage | Store at -20°C | | References | [1] Zhang L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020 Mar 20. pii: eabb3405. DOI:10.1126/science.abb3405 |
| | SARS-CoV-2-IN-1 Preparation Products And Raw materials |
|